PharmiWeb.com - Global Pharma News & Resources
10-May-2024

Genflow Biosciences PLC Announces Holding(s) in Company

LONDON, UK / ACCESSWIRE / May 10, 2024 / TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BP2C3V08

Issuer Name

GENFLOW BIOSCIENCES PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Jonathan Mark Swann

City of registered office (if applicable)

rickmansworth

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

09-May-2024

6. Date on which Issuer notified

10-May-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.030000

0.000000

5.030000

17586000

Position of previous notification (if applicable)

4.830000

0.000000

4.830000

16874000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)Number of direct voting rights (DTR5.1)Number of indirect voting rights (DTR5.2.1)% of direct voting rights (DTR5.1)% of indirect voting rights (DTR5.2.1)

GB00BP2C3V08

17586000

0

5.030000

0.000000

Sub Total 8.A

17586000

5.030000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrumentExpiration dateExercise/conversion periodNumber of voting rights that may be acquired if the instrument is exercised/converted% of voting rights





Sub Total 8.B1



8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrumentExpiration dateExercise/conversion periodPhysical or cash settlementNumber of voting rights% of voting rights






Sub Total 8.B2



9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling personName of controlled undertaking% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold





10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

NONE

12. Date of Completion

10-May-2024

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Genflow Biosciences PLC



View the original press release on accesswire.com

Editor Details

Last Updated: 10-May-2024